Accessbio

About Accessbio

Established in 2002 by Dr. Young Ho Choi, Access Bio is a publicly-traded company specializing in the research, development, and manufacturing of in-vitro diagnostic products. Dr. Choi, a Korean-American entrepreneur, leveraged his extensive background in veterinary medicine and research, which includes a DVM from Seoul National University and a Ph.D. from Gifu University, to found the company. His academic and research career, with a focus on ICSI and reproductive technologies at institutions like Texas A&M University, provided a strong scientific foundation for the firm.

Access Bio has become a significant player in the global infectious disease diagnostics market, initially gaining prominence for its work in combating malaria. A major milestone was achieved when its CareStart™ Malaria Rapid Diagnostic Test (RDT) was recognized as a top-performing product by the World Health Organization (WHO), leading to partnerships with major global health organizations like UNICEF and Doctors Without Borders. By 2013, the company had become the leading global supplier of malaria RDTs and was listed on the Korean Stock Exchange (KRX).

The company's business model revolves around the in-house development and manufacturing of diagnostic tests, which are then distributed to a global client base that includes non-profit organizations, private companies, and healthcare providers in over 120 countries. Revenue is generated from the sale of these diagnostic products. The product portfolio is diverse, utilizing immunochemical, biochemical, and molecular diagnostic technologies. Core offerings include Rapid Diagnostic Tests (RDTs) for preliminary screening, analyzers for measuring biological samples, and molecular diagnostics for analyzing genetic markers. Beyond malaria, their products target a range of infectious diseases, including COVID-19, Dengue fever, HIV, and HPV.